STUDIES ANALYSISOFTHEMECHANISMSOFACTIONOFBRYOMIXOLSTHERAPEUTICS OFACTIONOFBRYOMIXOLSTHERAPEUTIC Several years ago, the author, Cesar Bertacchini, M.D.

., and others decided to join together in promotingandmaintainingtheresearchbyArgentineinvestigatorsregardingaspectswhichwerebelieved necessaryinordertoreachdefinitivesuccessintheworldwidefightagainstcancer.Thedecisionwastobring themaincharacterofthisstruggleintothepicture.This,ofcourse,isthepatientwhohascancer. Joiningforces,throughtheResearchCenter,resultsweremadeavailabletothescientificandmedical teams of more than fifteen years of phytological investigations. In this study, every plant, every botanical specimengavespecificanswers.Theseanswersledtothewisdomandtheneedtoreturnto"primitive"or naturalmedicine,keepingthepatientinmindatalltimes. ThephysicianswhoweretrainedattheCenter,madegreatprogressduringmorethanfiveyearsin the research and application of homeopathic magistral formulas, comparable to those in the World HomeopathicPharmacopoeia, which aboveall would be found to be effective if the followingwere simply observed: a) That persons from any country such as ours who have ignored or neglected the advice of the Advisory Committee of the World Health Organization, which met in Geneva on November, 1962, to establish a permanentnationalprogramtofightagainstcancer,countriesinwhichevensmokingispromotedbymass communicationmediawhichareinthehandsofthegovernment,havenoincentivetofightagainstcancer. Theyarejustaccustomedtolivingwithcanceranddyingofcancer. b)Thatwearecompletelyconvincedthatimmunologicfactorsareinvolvedintheresistancetocancerandin the destruction of neoplastic cells. The cancer patient must be taken into account, and he must be made awareofthisprinciplesinceheisthemaincharacterinthisfight. c)ThattheWHOremindsusthatin1987"halfthediagnosedcancercasesandtwothirdsofthedeathsdue tothatcauseoccurredindevelopedcountries."Giventhis,weindevelopingcountriesdonotstandevena chanceofbecomingdeveloped.Cancerinthosedevelopingcountriesismoreprevalentandtakesagreater tool.Thestruggleandthechallengeareinthesecountries,andwemustbeginnow. d)Thatnocurativeprocesscanbeginifthereisnohope.Hopecanbefoundonlyifthepatientbelievesthat somethingorsomebodycanhelphimgetwell.Dr.BernieS.Siegelremindsusthat,"hopeisgoodmedicine." Thatiswhytoday,itisapleasuretoprefacethishumblepropositionmadetotheinternational scientificcommunity,whichproposesarestatementoftheproblemandasksustoponderaboutthetwo maincharactersinthefinalsuccessinthefightagainstcancerwithoutwhichthebattlewillhavenosuccess andeverypropositionthatdoesnottakethemintoaccountisboundtofail:THEPATIENTandTHE PHYSICIAN.Italsoproposesayouthfulattitudeofrebellionwhichisgoodforscience:insteadoflivingwith evilwemustdestroyit.Weshouldevenimprintthatrebelliousnessinthegeneticmakeupofeveryhuman being.Thatiswhereultimatelyoursuccesswillcomefrom. BuenosAires,Argentina July,1991CesarBertacchini,M.D.

BRYOMIXOL:ANUNCONVENTIONALTHERAPEUTICMETHOD Faced with the need to present to the scientific community for its judgment the effectiveness and possible mechanisms of an unconventional therapeutic method, the first thing we must face and defeat is skepticism.Tohelpusdothat,letusrememberwhatProfessorGregorioAraozAlfarosaidin1927:"Nothing issufficient.Hewhobelieveshehasthedefinitivetruthliestranquilandsecureinhiserror." Ontheotherhand,weneedtomakeitveryclearfromthebeginningthatourmethodmeetswhatwe believetobethemainruleinmedicalpractice:"Primunnonnocere*"whichhasbeendemonstratedinour experiencewithanimalsandinthousandsofpatientswhohavereceivedthetreatmentinthelastfewyears. Thishasoccurredalthoughwehaveusedintramuscularorintravenousadministrationdaily;withanalmost nonexistentincidenceofabscessesorcomplications,lessthanusuallyoccurswithsuchadministrations. Called "Homeopathics," a name given substances used in our medication because they are not measurable or undetectable by methods which science has at present, we will try to apply a rigorous semanticandscientific approach to thissubject.Homeopathic Medicineis defined asthat which isusedto produceacureinthepatientthroughtheapplicationofsubstanceswhicharecapableofproducingthesame symptoms the disease causes. Drugs used are given at maximum dilution since a measurable dose can be toxic.Homeopathictheorysaysthatthegreaterthedilution,thegreatertheeffect,sincethepropertiesof thedrugsareultimatelytransmittedbythemolecularmemoryofwater. Giventhisaffirmation,itwouldbelogicaltoaskoneselfiftheeffectsofthismedicationareproduced by the presence of the molecules which are there in quantities undetectable by present technology. This possibilityisverymuchinagreementwithscientificlogic,especiallyifwekeepinmindthehighsensitivityof somecellularnervereceptorsinlivingorganisms.Forexample,itisknownthathumanolfactorycellsdetect substances such as methylmercaptan in concentrations of 1/25 bilLyonth of a milligram per milliliter of air. Whythencouldwenotacceptasaworkinghypothesisthepossibilityoftheexistenceofsometypeofsimilar receptor at the level of the immune system capable of capturing substances in extremely low doses and reacting positively at that dosage? For example, it is known that numerous vegetable substances produce mitosisinleukocytesgrown"invitro."PhytohaemagglutininextractedtheplantFaselousVulgaris(redbean) is capable of stimulating the cellular reproduction of "T' lymphocytes "in vitro" in optimum fashion in a dosageof100ugr/mlandhasnoeffectat10ugr/ml.Italsohasnoeffectonceconcentrationexceeds1200 ugr/ml. Fromthiswecandeducethatagreatmanysubstancesmusthavesimilaractionsatcertain concentrations,suchasdoesConcavalineAwhichisextractedfromConcavaliaEsiformis(broadbean)which stimulatesagroupof"T"lymphocytesdifferentfromtheonewhichPHA(phytohaemagglutininA) stimulates.ThemytogenofPhytolaccaAmericana(PWM)stimulates"B"cellsandasubgroupof"T"cells. Cases.Tumoralareas The numerous cases which were treated showed a positive clinical response in greater or lesser degree.Theearliestcaseswerestudiedintensivelyandwerereadiedforpublication. Thetumorsthatrespondedtoagreaterdegreetoourtreatment,aswasexpected,aretheoneswith the greatest degree of undifferentiation; because of their antigenic characteristics and because of the greaterdegreeofdissimilaritybetweenthemandthegenotypesandantigeniccharacteristicsofnormalcells, theyhavemoreprobabilityofelicitinganefficientimmunologicresponse.

Histologicalstudieswhichweremadegiveuscertainpossiblemechanismsofactionwhichcorrelate withtheclinicalresponseobtained. Microscopic studies showed the almost complete delimitation of the tumoral areas by connective vascularstructureswhichseemtohavediversemorphologiesaccordingtotheirproximitytothetumorand the level of their chronological development, having at first a thick endothelial wall with lymphocytic infiltrates with convoluted nuclei that on occasion can be observed piercing the vascular walls in afashion similartothepostcapillaryvenulesof"T"originofthelymphaticgangLyon. Thesevesselsapparentlyevolvetowardhyalinizationandthinning,becomingsurroundedwithdense connectivetissueinlaterstagesandresultinginakindofinterconnectedvascularnetworkwhichisrepeated inanobservablemannerinthedifferentspecimenswhichwerestudied.Ineverycase,inthevicinityofthe vessels and peri and intratumoral areas, the presence of numerous mastocytes was observed using the Giemsa technique (these cellular elements were considered a good prognosis in some of the work in mammarycarcinoma). Another notable characteristic is the leukocytic barrier which appears in the contact zone with the tumor.Inallprobabilitythatiswhereallkindsofimmunoactivephenomenadevelop,sincethatiswherethe greatestconcentrationofmacrophageand"T"cellsisevidenced. Before continuing with the histologic descriptions we must take a brief pause in order to quote a morphologicprecedentofthechangesobservedinthesecases. In a study, Ray and his associates in 1982 investigated the response to extracorporeal plasma immunoabsorptionwithnonviableStaphylococcusAureasinametastasizedadenocarcinomaofthecolon. On this occasion, the monthly serial biopsies of a metastasized umbilical mass demonstrated the presenceofneovascularizationwithpolymorphonuclear,eosinopphilicandplasmocellularinfiltratethefirst month;afterthat,progressivehyalizationoftheestromaappearedwithformationofflatepithelialvessels like the ones observed in our cases and changed in the infiltrate with a greater amount of mononuclear cellularelementsandplasmocyticfocalareas. The difference in our studies is in the amount and extension of the appreciable necrosis which is clearly greater than the one observed by Ray and his associates. Another difference is the absence of eosinophils in all our cases and the constant presence of mastocytes (or primed cells) which, as we mentioned,somewritersassociatewithabetterprognosisinmammarytumors. The studies in immunohistochemistry made on the specimens allowed us to demonstrate the overwhelming presence of macrophage in tumoral borders. These were also associated to neovascular structuresandtointratumoralsectors. Thenumberof"T"lymphocytesobservedwasalsogreaterinthetumoraledgesandintheperivasculararea; "B"lymphocytesturnedouttobelessnumerousandpredominantlyperivascular. Weareconvincedoftheimportantrolethatthesecellularelementsplayintheresultsobtainedby Bryomixol. In many publications they are the ones believed to be capable of interacting with vascular endothelialcells(presentalsoingreatnumbersintheproductionofinterleukinesII,I16,GMCSF,MIF,etc.) andtheimportantTNF(TumorNecrosisFactor).ThroughtheTNF,macrophagesstimulatetheproductionof other TNFmARN macrophages (ARN messenger of TNF), which with the stimulation of other leukokines is transmittedanewtotheTNFprotein.

 In its interaction with endothelial cells, TNF produces the expression of membrane adhesion structures: ELAM 1 and ICAM 1 (endothelial cell leukocyte adhesion molecule 1 and intercellular adhesion molecule1)whichfavorselectivelytheisolationof"T"lymphocytestothevascularwallandtheirousterfrom thetissues. In addition to their cytotoxic functions, "T" cells favor the appearance and differentiation of mastocytes through IL3 (interleukin 3); the activated mastocytes interact with the fibroblasts by making themlosetheirinhibitionbycontact(demonstratedintissuecultures),favoringcollagenosisandfibrosis. Itisknownthat"T"lymphocytesarecapableofstimulatingbyaggregationtheaffluenceofcellsfrom the "B" sector, themselves detectable by immune markers and expressed by the marked activated plasmocytespositivelymarkedforKappaandLambdachains. Insummary,fromthestudyofthecellelementspresent,thereisevidenceofawellstructuredand developedactiveimmunephenomenon,ofwhichsector"T"ismainlyassociatedadequatelywithelements ofsector"B"anditshighnecrotizingeffect,demonstratedbytheintensetumoralnecrosisobservedinthe specimensstudiedmicroscopically,whichreaches80%inthecaseofcarcinomalmetastasisofrenalcells.This contrasts with that observed when there is a peritumoral inflammatory reaction in cases not treated with BRYOMIXOLtherapeuticsinwhichtheoppositeoccurs:numerouslymphoidelementswhichareincapableof destroyingthetumor. TUMORALCELLS.THEBRYOMIXOLWAY Another important element to keep in mind is the response of tumoral cells themselves: an outstanding characteristic observed in treated cases is the presence of abundant aberrant cellular, nuclear andmitoticabnormalitiesinthemalignantcells.Thechangesaresoevidentthattheysuggestthefindings produced by other treatments (radiotherapy or chemotherapy), although these may have not been administered to the patients studied. This probably leads the tumoral cells to a greater lability for less differentiationandtowardagreatertendencytoabortivemitosis.Thismechanismitselffeedstheimmune chainagainwhenitliberatescellularbreakdownproducts,whichsurelywillformpartoftheagentsthathave thecapacitytoelicittheantigenicresponse.Moreover,thecellulartoxinswhicharetheproductoftumoral necrosis provoke intratumoral inflammatory and thrombotic phenomena, which increase the possibility of theirdestructionduetodecreaseoftumoralirrigation.Thisphenomenonishomologoustothatobservedin transplantedtissuerejection,inwhichantibodiesbecomefixedinthevascularendotheliaofthetransplanted organs,provoking the activation of the fragmentsof the complement and serving as the substratefor the adhesion of the polymorphonuclear leukocytes which at the same time destroy the endothelial cells, permittingtotalorpartialplaqueaggregation,coagulationandvascularobstruction. Itis interesting to note in regard to thislastmechanism that the arterioles and smallarteriesshow phenomena ofvasculitisbutnotofthrombosis.Inturn,thevenousvesselswhichtheoreticallyremovethe productsofthedestructionofthetumorshowthromboticphenomena. Themarkedatypiesalreadymentionedleadustotwopossibleanalyses:ononehandwecandeduce that the activation of the defense mechanism produces, by means of antibodies and cytotoxic complexes actingonthetumoralcells,intraandextracellularormetabolicalterationswhichincreasethedifferentiation of atypical cells. This could be interpreted as an epiphenomenon of a general stimulation of the immune system.

On the other hand we can suppose that the BRYOMIXOL treatment, acting as a general mitogenic and stimulant at the level of all the cellular components of the organism, besides influencing the immune system, also influences atypical cells favoring their mitotic reproduction and provoking greater undifferentiation. In the case of malignant or very slightly differentiated tumors, this phenomenon could resultinadestructiveeffecttothetumoritself. We imagine that the tumoral microclimate is an unstable system in crisis, bordering in nutritional insufficiency and hypoxia, because of its characteristics and by the histological evidence by which highly malignant tumors frequently display numerous necrotic areas. Let us imagine a tumoral microenvironment borderingonhypoxiaandmetabolicacidosisduetolackofirrigation,stimulatedtoamassiveactivecellular reproduction. In this model no doubt the result would be tumoral necrosis. This, in conjunction with the general actionandtheactionontheimmunesystembytheBRYOMIXOLmedication,wouldallowthedestructionof tumorsbymeansofthemetabolicmechanismononehandandbyabortivemitosisandresultantnonviable cells on the other, and finally by direct active cytotoxic destruction by the delayed (cellular) action of the immune system. At the same time, this viewpoint would present the best answer to radiotherapy and chemotherapythat95%ofourpatientsrefertoandwhichweevaluatebydiagnosticimagingmethods. Radiotherapy as well as chemotherapy is highly effective in cells which are in the stage of cellular divisionorinthestageofthesynthesisofADN.Itisevidentthatifthetumorisgreatlystimulated,itsliability willbegreater. Coupling these speculations with the idea that the Bryomixol method is an adequate general stimulant,wecanexplaintheimprovedsubjectiveresponsethatallourpatientshavehadtochemotherapy. They have let us know that they notice great differences in the incidence of vomiting, nausea, headaches, etc.,whentheyareundertheBRYOMIXOLtreatmentincomparisontoothermethodologies. Likewisethehighandrapidrecoveryofthehemogramvaluesisnoteworthyinpostradiotherapyas wellasinpostchemotherapy;andwithinthehemogramvaluesthestimulantofmonocytesisquiteevident. Intreatedpatientsthemonocytecountvariesfromtheusual2%to3%upto5%or6%andevenupto8%,this lastvaluebeingincasesthatrespondbest. Thisoccurredinapatienttreatedformultiplemetastasisofkidneycellcarcinoma,whodemonstrated asustainedelevationofmonocytesatthebeginningofthesecondmonthoftreatment,whichcontinuedto be8%after14months,withdisappearanceofmetastasisandevenoftheuntreatedareaofthekidney. MACROPHAGEANDTUMORALBORDERS Asiswellknown,monocytesarethecirculatingprecursorsofhisticmacrophages.Thesearecellular components capable of being stimulated experimentally to reproduce and be activated; for example, in pleuroperitonea cavities with the injection of bacterial antigens. These have been the subject of studies in animalandhumanexperimentationthroughthedirectactivationbyCornebacteriumParvum,BCG,etc.,and indirectstimulationthrough"T"lymphocytesbythesesameorganisms,asamodelforantitumoralimmune therapeutics.

It has been known for some time that macrophages, when activated, possess divers "loci" of receptioninthecellularmembrane, beingabletoattachthemselvestocomponentscoatedwithIgC,toa fraction of the C3G complement, to the walls of microorganisms and to vegetable lectin. Perhaps future investigations may help us find the possible compounds which at low dosages elicit the response of macrophagicactivationandtofindthattheymayberelatedtothesevegetablelectin. Thehighconcentrationsofmacrophagesfoundintumoralbordershavenotbeendescribedbyother researchersengagedinthisfield.Onthecontrary,in1989Norazmietal.,whilemakingcomputerizedvideo images, discovered that normal tissues possess a significantly larger number of mononuclear cells (lymphocytes,macrophages)thantumortissuesinpatientswithcarcinomaofthecolon.Afteranalyzingthe infiltratesqualitativelyandquantitatively,theydiscoveredthatmacrophageswereabsentorpresentinlow numbersinthetumoralborders.ThisdatacoincideswiththatofCsibaetal.donein1983andwiththatof Rowetal.conductedin1984regardingmammarytissueswithcarcinoma. Regarding macrophage, in 1985 Mantovani and Evans declared that since these are active against tumorsinandofthemselves,theirusualdecreaseinperitumoralareascouldberesponsibleforthereduced antitumoralresponseofthehost. TheclinicalactionoftheeffectsoftheBRYOMIXOLmedicationcanbeseeninthenumerouscasesas thatofapatientwithmetastasisofrenalcarcinomawhoshowedahighlyfavorableevolutionofhiscerebral metastasiswheninDecember1,1989,hehadshownaterminalpicture,accompaniedbycutaneous,hepatic and pancreatic metastasis. He was treated with only 5000 cranial Rads and no other therapy besides the BRYOMIXOL method. We find him 14 months later in a perfect state without hepatic and pancreatic metastasisandwithareductionofthecerebralmetastasisshowingscarfociwhichseemtobecalcified. Acutaneousmetastasiswhichwasexcisedafter4monthsundertheBRYOMIXOLtreatment,which hadshrunktohalfofitsoriginalsizewithoutanyadditionallocalorgeneraltreatment,allowedustoconduct oneoftheobservationswithimmunemarking. Another very interesting case allowed us to observe the reduction of a hepatic metastasis of mammary adenocarcinomauntilitdisappeared. AnotherveryinterestingcaseifthatofapatientwithundifferentiatedCavumcarcinoma,whoduring radiotherapy showed tumoral increase instead of decrease. Upon beginning BRYOMIXOL treatment he showedarapidclinicalandtomographicimprovement,andisnowinperfectgeneralstatewithoutrecidivism ofhisdisease. BRYOMIXOL:AJOINTTHERAPEUTIC There are many cases like the ones cited in which BRYOMIXOL therapeutics, either alone or in conjunctionwithradiotherapyorchemotherapy,havebeenabletoreduceandevenremovemetastasisand primarytumors.Itsactionvariesinrelationwithfouraspectsofthediseaseasfollows: 1)Thestageofinvasionofthemalignancyand,aboveall,thewholevolumeofthetumoralmass.Thelarger thetumoralmass,themoredifficultitistocure,whiletheoppositeistrueinsmallermasses(evenincasesof cerebralorhepaticmetastasiswhentheseareisolatedorsmall).

2)Thetypeoftumor.Themoreundifferentiatedthemalignancy,thebettertheevolutionandhistology.The caseswiththeleastspecificantitumoralresponse(evenimprovingthegeneralstateofthepatient)arefound inwelldifferentiatedtumorsthathavealowdegreeofaggressiveness. Thissuggeststhatwhenthehistologicaltypeismoresimilartothenormalcellsofthehumanorganismthe possibilityofexhibitingantigenscapableofelicitinganadequateimmuneresponseissmaller. 3)Theageandgeneralstateofhealthofthepatientareimportant.Theyounger,thegreatertheresponse; the healthier, the better possibility of reaction. We assume that this has to do with the integrity of the immunesystem. Itisknownthatineveryspeciesoldageresultsinthedecreaseofdefensemechanisms.Itisprobable thatthereisatotallossoftheclonesofthemothercellsimmunologicallyexcitableinthebonemarrow,the spleenandthelymphaticganglia(organswhichtendtoatrophyanddecreaseinoldage). ThetreatmentsassociatedwithBRYOMIXOLtherapeuticsarenodoubtresponsibleforthediversity ofresultsobserved.Forexampleweareinapositiontopropose,notwithstandingthatinordertocometo more definitive conclusions more research is needed, that the adjunct of radiotherapy in localized sectors which do not affect the individual, globally altering his immune system, is highly positive. The more spectacular cases in tumoral remission have been obtained with this adjunct. On the other hand, chemotherapy even with BRYOMIXOL medication, becomes attentuated rapidly as far as its subjective progress (vomiting, nausea, headaches, appetite, general state (and its subjective progress (hemogram, resistance to infections, capacity for physical activity, etc. does not show spectacular reduction of the tumoralmasses.Anexceptioninthistendencyhasbeeninsomecasesofcarcinomaofsmallpulmonarycells (oat cell carcinoma) and other undifferentiated tumors of the neuroblastoma and acute leukemia types in childrenwhichshowmarkedimprovement. Thebalancingofthesefourvariables,thatis:1)tumoralsize,2)histologicaltype,3)ageandgeneral state,and4)adjuncttherapy,giveusthenecessaryelementsforapreliminaryprognosisofthepossibilities oftreatmentineachcase. Wearewellawarethatthisisasubjectwhichmustbeintenselystudiedinthefuturewiththesameor evengreaterintensitythanthebasicresearch(mechanismofaction)inordertobeabletofacewithcertainty thetreatmentofeachtumoraltypeoreachparticularcase. At present, a short five years in which the BRYOMIXOLmethod has been in use, we are not inthe positiontoadvisethepatienttoabandonanyoftheclassicalmethodsoftreatmentsavailable.Thelatterin many instances are merely palliative without stopping the advance of the disease, while at the same time they destroy the patient's immune system so that when the therapy is suspended or no other therapy becomesavailable,thetumoralprogressionisinexorablebecausethedefensemechanismsandthegeneral stateofthepatientaredevastatedwithouthavingachievedtheeliminationoftheneoplasm. InconcludingthisbriefintroductiontoBRYOMIXOLtherapeutics,wecanstatethatwefindourselves withamethodoftreatmentagainstneoplasmswhichisinnocuousandhasmanyadvantagesduetotheease ofitsadministration,highdegreeoftolerance,anditsprovenbeneficialeffects. Amongtheseeffectswecancite: 1)Anincreaseintheantitumoralimmuneactivitywhichisdemonstratedhistologicallyintheincreaseofthe destruction and necrosis of tumors, with marked difference in the composition of the peritumoral

mononuclearinflammatoryinfiltrate,theoppositeofthatobservedincasesnottreated,withanincreaseof macrophageand"T"lymphocytes. 2)Abettertoleranceincomparisonwithunusualoncologicaltreatments(radiotherapyandchemotherapy), demonstrated by the subjective manifestations of the patients and by laboratory tests, with a more rapid recoveryofthehemogramandgeneralstate. 3) Objective reduction of the tumor size through imaging studies conducted on patients treated with BRYOMIXOLtherapeutics,eitherbyitselforinconjunctionwithotherclassicalmethods. 4)Extensionofthelifeexpectancyofpatientsdiagnosedasterminal.Thisextensioninallcasesexceededthe forecastbyseveralmonthsandinsomecasesacurewasachieved. Given these facts, we tend toward a deepening of our studies of the mechanisms of action, which almost surely are related to the stimulation and activation of macrophage and "T" cells by one or several of the substancesweuse. Thesemechanismshavehomologin,forexample,thestimulatingactivityofCD4Tlymphocytes("T"helper) in humans, which is contained in Jacalina, which is extracted from the seeds of Astrocarpus Heterophillus. Moreover the presence of receptors for nonopsonized sheep erythrocytes has been effectively demonstrated, lectinsimiles in murine macrophage; a system that is capable of effecting hemopoiesis and immunocompetenceofmacrophagesthroughinteractionwithsialinizedglucoconjugates. All this information leads us to plan future studies in stimulation in vitro of macrophage and "T" lymphocytes, as a means to obtain convincing certification of the mechanism of action at a level of basic investigationandalsotodeterminetheseriallymphocyticsubgroupsinpatientsundertreatment. Themarkedatypiesalreadymentionedleadustotwopossibleanalyses:ononehandwecandeduce that the activation of the defense mechanism produces, by means of antibodies and cytotoxic complexes actingonthetumoralcells,intraandextracellularormetabolicalterationswhichincreasethedifferentiation of atypical cells. This could be interpreted as an epiphenomenon of a general stimulation of the immune system. On the other hand we can suppose that the BRYOMIXOL treatment, acting as a general mitogenic and stimulant at the level of all the cellular components of the organism, besides influencing the immune system, also influences atypical cells favoring their mitotic reproduction and provoking greater undifferentiation. In the case of malignant or very slightly differentiated tumors, this phenomenon could resultinadestructiveeffecttothetumoritself. We imagine that the tumoral microclimate is an unstable system in crisis, bordering in nutritional insufficiency and hypoxia, because of its characteristics and by the histological evidence by which highly malignant tumors frequently display numerous necrotic areas. Let us imagine a tumoral microenvironment borderingonhypoxiaandmetabolicacidosisduetolackofirrigation,stimulatedtoamassiveactivecellular reproduction. In this model no doubt the result would be tumoral necrosis. This, in conjunction with the general actionandtheactionontheimmunesystembytheBRYOMIXOLmedication,wouldallowthedestructionof tumorsbymeansofthemetabolicmechanismononehandandbyabortivemitosisandresultantnonviable cells on the other, and finally by direct active cytotoxic destruction by the delayed (cellular) action of the

immune system. At the same time, this viewpoint would present the best answer to radiotherapy and chemotherapythat95%ofourpatientsrefertoandwhichweevaluatebydiagnosticimagingmethods. Radiotherapyaswellaschemotherapyarehighlyeffectiveincellswhichareinthestageofcellular divisionorinthestageofthesynthesisofAND.Itisevidentthatifthetumorisgreatlystimulated,itslability willbegreater. Coupling these speculations with the idea that the BRYOMIXOL method is an adequate general stimulant,wecanexplaintheimprovedsubjectiveresponsethatallourpatientshavehadtochemotherapy. They have let us know that they notice great differences in the incidence of vomiting, nausea, headaches, etc.,whentheyareundertheBRYOMIXOLtreatmentincomparisontoothermethodologies. Likewisethehighandrapidrecoveryofthehemogramvaluesisnoteworthyinpostradiotherapyas wellasinpostchemotherapy;andwithinthehemogramvaluesthestimulantofmonocytesisquiteevident. Intreatedpatientsthemonocytecountvariesfromtheusual2%to3%upto5%or6%andevenupto8%,this lastvaluebeingincasesthatrespondbest. Thisoccurredinapatienttreatedformultiplemetastasisofkidneycellcarcinoma,whodemonstrated asustainedelevationofmonocytesatthebeginningofthesecondmonthoftreatment,whichcontinuedto be8%after14months,withdisappearanceofmetastasisandevenoftheuntreatedareaofthekidney. CANCERTODAY Thearsenaloftechniquesandmedicationsthatarecurrentlyatthedispositionofmedics,allows them to cure only one fourth of the diseases that attack humankind, the rest are incurable or self limitating,andtheyhealbythemselvesinsomeway. The doctor of today is at risk of being crushed by a great amount of information, and overwhelmed by technology, in a way in which, while healing science progresses, the art of healing, is reducedtoaromanticimageintheworldofmedicine. Thereissomeelementintheconscienceofeverypatientwhichmakesadifferenceinthereaction ofthebodytothediseaseanddiversetreatments,insomethingasephemeralasanattitude,agestureof the medic, or feeling, can leave its trace in the organism, relieving incertitude, any prognostic or therapeuticalanswer. Thereality is that cancerexists, persists and resists all the attempts and experiences madeuntil todaytoachieveitsdefinitivecure,onlygreatersuccessesintheareaofeducation,preventionandearly diagnosiswereobtained,achievingsensiblediminishmentinmortalitybycancerratesintheU.S. It is for such reason that the efforts of today are oriented towards greater knowledge of the cancerpromotingriskfactors,andtheirprevention. The introduction of systemic adjuvant and complementary immunostimulating therapies suchas BRYOMIXOL increased the diseasefree period, producing in relative terms, a reduction of specific mortalitybetween40%and50%.

Despitetheadvancesinthetreatmentandknowledgeofcancerbiology,theresult,inmetastasis to distance, even with the incorporation of new drugs, is discouraging, in the last 20 years, significant changeswerenotnoticedinthegroupofpatientswithbreastcancerthattookonlyclassictreatments,as anonlytherapeuticalresource. Today,manybiologicalstrategiesappear,thatincludemonoclonalantibodies,Immunoconjugated andgenetictypetherapies,buttheirevaluationrequiresmanyyearsofstudy. Today,thereisatakingofconscience,aboutthatactually,followingSirWilliamOslerItsmore important to know the type of patient that suffers from a disease, that the disease the patient suffers fromIfwecantakethetermdiseaseandchangeittoCANCER,wewillhaveanewvision,fromwhere tounderstandbettertheevolutionandthedifferenttherapeuticalpointsofview. Everypatientisauniqueindividualandisrelatedwithhisownpreexistentbiologicalconditions, thepsychosocialevents,andthedisease. FreudupholdsthatTheemotionsthatarenotmanifestedwithactsorwordsfindtheexpression onsomefiscalalteration.Itspossiblethatemotionsopenthepathfortheunleashingadecreaseinthe immunological systems potency in a predisposed organism, and that way start the process towards cancerdevelopment. Asitisalreadyanacquiredrightofmankindtoitshealth,demandfromthepatientanditsfamily for answers and solutions to the crisis that the disease poses is growing, as doctors, we have the obligationtosatisfyitonewayoranotherbutalwaysprivilegingtheneedsandemotionsofthepatient beforetheonesofactingmedic. Weshouldntdisqualifyanytherapeuticmethodsagainstcancer,capableofproducingsomekind of remission because we dont know the intimate action mechanism; any treatment of an advanced cancer that produces some kind of positive response is of biological interest justifying studies and our attentiontoevaluateitsclinicalpotential. Thevalueofthetherapeuticresponseshouldnotbeorientedonlytotheremissionofthetumor and the duration of the same but also to the life quality indexes such as physical performance psychic situationandthewellbeingofthediseased. In the same way in which some emotional factors can contribute to the development of cancer otherscancontributetoitsregression,itsourdutytogetinvolvedwitheachpatientsproblemsandhelp themholdandreinforcetheircapacitytofacethediseaseineveryleveleven,psychologically. Wheneverweproceedwithintelligence,precaution,sensitivityandtruecommitmenttheresults arehonestlypositiveasmuchforthepatientasfortheoncologist,asarevelationtohimthatthespecialty mayalsoofferthesidesofhopeandgratificationsbeforethevicissitudesofcanceranditstreatment. Itsessentialasadoctorinfrontofthepatienttotakeconsciousnessthateventhoughthereisnt a specific therapy for this case there always will be a resource that can and must be done to help the patient and his family to bear the experience, abstention, if considered a therapeutic behavior in some occasion,eliminatesallhope. PUBLICACIONESEDITADASENDIVERSASREVISTASDEPSICONCOLOGA

 RELATIONSHIPBETWEENONCOLOGICALPATIENTS ANDHISDOCTOR It results surprising to me to observe in occasions the link between the doctor and the patient, whichshouldbestrongandcommitted,itbreaksdownwhenthediseasedwithitsdiminishedself,itsbody imagealteredand its fears facing the impersonal and authoritarian distance from some of its colleagues, then due to fear of criticism or abandonment, they hide deliberately their internal need to find a new approach to the doctorpatient field of interaction, in their search for answers to relieve their existential crisisinthefaceofcancer. Totheguiltthatthediseasecreatesforitselfyoucanaddtheguiltofdeceit,inhidingduetofearof hisoncologist,whoalsoasacomplementtochemotherapydoeswithmeanonconventionaltreatment. Then the patient feels confused and alone with the impossibility of transmitting its angst in the intimate environmentoftherelationshipwithwhoshouldbehisleadingdoctorresponsibleforhisfuture. Whoeverdoesntunderstandthisphenomenonwillinevitablyloosetheveryessenceofthemedical act, and his patient who bestows on him more than just his confidence and fidelity of a renewed relationship, hidden to the eyes of the oncologist who from that point on will become a necessary instrumenttohismedicalinsurance,asmaximumexpressionofcoldtecnisism,distant,evenfeared,onthe deceasedsfantasy. Every doctor says that according to his personal history, his moral, cultural, scientific upbringing, his decisionsandthecriteriatofollow,inaccordancetothetreatmentandthediseasedsubject. Whatinmypointofviewisunforgivableistheabandonmentortheintoleranceeventhenagging thatofsomeofmycolleaguestransmittothediseased,whenthefamilyorthepatientinthefaceofcrisis gives a hintof the possibility of recurring to a complementary or non conventional treatment that might help him if it doesnt fit in the rigorous scientific method that has been incorporates a reassuring sustenanceofitsdecisions Wehavetorealizethatthelawsandtruthsofsciencearerelatedtothelawsandtruthsofscience andhumanneeds Theexperienceoftheoncologistasanindividualhispersonalexperiencesofjoyandsorrow,areof greathelpwhenitcomestounderstandingthecrisisandanguishofthepatientandthefamilywhenfacing thelifethreateningriskthatimpliesthediseaseandthedifferentcircumstanceswiththeirsurroundings. Evenwhenitsaproductofmansciencedoesnt understandthepowerofhumanemotionasits postulates step away from all subjectivity , but there is a middle point between the doctor patient consciousness,itstherewhereitsbornbeyondallscientificbordersandanytherapeuticallyprincipal